Randomized, placebo-controlled, double-blind study to assess clinical and antiviral activity of valomaciclovir (EPB 348) in infectious mononucleosis due to primary Epstein-Barr virus infection (Mono 6)

Trial Profile

Randomized, placebo-controlled, double-blind study to assess clinical and antiviral activity of valomaciclovir (EPB 348) in infectious mononucleosis due to primary Epstein-Barr virus infection (Mono 6)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Valomaciclovir (Primary)
  • Indications Epstein-Barr virus infections; Infectious mononucleosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Mono6
  • Most Recent Events

    • 02 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2009 Results were presented at ICAAC 2009.
    • 14 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top